LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

545.56 -1.57

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

543.63

Max

554.7

Belangrijke statistieken
By Trading Economics
Inkomsten	-72M -114M
Verkoop	74M 287M
EPS	-4.956
Winstmarge	-39.75
Werknemers	528
EBITDA	-75M -114M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+5.32% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.5B 13B
Vorige openingsprijs	547.13
Vorige sluitingsprijs	545.56

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 dec 2025, 23:50 UTC

Populaire aandelen

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

17 dec 2025, 23:20 UTC

Winsten

Correction to Micron Logs Sales Jump Article

17 dec 2025, 23:07 UTC

Winsten

Micron Logs Sales Jump, Sees Further Growth as AI Demand Outpaces Supply -- Update

17 dec 2025, 21:37 UTC

Winsten

Micron Technology 1Q Sales Jump 57%, Led By Memory Growth

17 dec 2025, 23:53 UTC

Marktinformatie

Gold Edges Higher, Supported by Some Tailwinds -- Market Talk

17 dec 2025, 23:43 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

17 dec 2025, 23:06 UTC

Acquisities, Fusies, Overnames

Asahi Group: Transaction Expected to Be Closed in 2H of Calendar Year 2026

17 dec 2025, 23:05 UTC

Acquisities, Fusies, Overnames

Asahi Group: Currently No Plans of Issuing New Shares in Asahi

17 dec 2025, 23:04 UTC

Acquisities, Fusies, Overnames

Asahi Group: Funds to Be Provided Via Borrowings From Financial Institutions or Cash on Hand

17 dec 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Asahi Group: Acquisition of 53.68% Stake in UDV (Kenya) is $646M on Equity Value Basis

17 dec 2025, 23:02 UTC

Acquisities, Fusies, Overnames

Asahi Group: Acquisition of 100% Stake in Diageo Kenya is $2.354B on Equity Value Basis

17 dec 2025, 22:59 UTC

Acquisities, Fusies, Overnames

Asahi Group: Deal Part of Strategy Under Medium- to Long-Term Management Policy

17 dec 2025, 22:57 UTC

Acquisities, Fusies, Overnames

Asahi Group: To Indirectly Acquire 65.00% Stake in East African Breweries PLC

17 dec 2025, 22:56 UTC

Acquisities, Fusies, Overnames

Asahi Group: Stakes Acquired From Two Subsidiaries of Diageo Plc

17 dec 2025, 22:55 UTC

Acquisities, Fusies, Overnames

Asahi Group Holdings: To Acquire 100% Stake in Diageo Kenya Ltd., 53.68% Stake in UVD (Kenya) Ltd.

17 dec 2025, 22:49 UTC

Marktinformatie

Sandfire Resources Production Pipeline Strength Questioned -- Market Talk

17 dec 2025, 21:58 UTC

Winsten

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17 dec 2025, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

17 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 dec 2025, 21:46 UTC

Winsten

Salesforce and Other AI Stocks That Can Catch Up to the Pack -- Barrons.com

17 dec 2025, 21:20 UTC

Winsten

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17 dec 2025, 21:10 UTC

Winsten

Micron Beats Earnings. The Stock Is Rising. -- Barrons.com

17 dec 2025, 21:05 UTC

Winsten

Micron Technology Anticipates Business Performance to Continue Strengthening Through FY26

17 dec 2025, 21:04 UTC

Winsten

Micron Technology: 2Q Outlook Reflects Substantial Records Across Rev, Gross Margin, EPS and Free Cash Flow >MU

17 dec 2025, 21:04 UTC

Winsten

Micron Technology Sees 2Q Oper Expenses $1.56B, Plus or Minus $20M >MU

17 dec 2025, 21:03 UTC

Winsten

Micron Technology Sees 2Q Adj EPS $8.42, Plus or Minus 20c >MU

17 dec 2025, 21:03 UTC

Winsten

Micron Technology Sees 2Q EPS $8.19, Plus or Minus 20c >MU

17 dec 2025, 21:03 UTC

Winsten

Micron Technology Sees 2Q Revenue $18.7B, Plus or Minus $400M >MU

17 dec 2025, 21:02 UTC

Winsten

Micron Technology 1Q Operating Cash Flow $8.41 B >MU

17 dec 2025, 21:01 UTC

Winsten

Micron Technology 1Q Rev $13.64B >MU

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

5.32% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 584.09 USD 5.32%

Hoogste 670 USD

Laagste 523 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.